Last month, ThromboGenics NV presented the results from the successful microplasmin MIVI-TRUST Phase III program at the EURETINA (European Society of Retina Specialists) Congress in Paris, France (MIVI-TRUST is short for “Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment”).

The MIVI-TRUST program is the largest interventional clinical program ever performed to specifically evaluate the vitreoretinal interface in patients with retinal disorders, involving a total of 652 patients at 90 centers across the U.S. and Europe.

The results showed the potential of microplasmin injections to transform the treatment of a range of retinal disorders. Specifically, the Phase III program showed that microplasmin injections:

• Were successful in resolving vitreomacular adhesion (VMA) (also known as vitreomacular traction)
• Were able to cure full thickness macular hole (FTMH) without the need for surgery
• Delivered an improvement in the vision of patients without the need for surgery
• Were safe and well tolerated; there was no evidence of an increased risk of retinal tear or detachment

Read the full ThromboGenics release here ^[1] (PDF).